undamentalytics Newsletter
Sign in

Rxsight, Inc. (RXST) stock

Add to watchlist

Add holding +

NASDAQ: RXST Nasdaq Health Care Equipment Next results ~November 3, 2026

C Fundamentals grade

Rxsight, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$4.3

Valuation models combined (3)

Base case. Range ~$4.2–$4.4. Weighted average of 3 models (growth cash-flow model, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Rxsight, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 4 selling0 purchases and 4 sales by directors and officers, last 12 monthsInsider trades
  • Funds94 adding, 69 cuttingOf 41 active managers that changed their stake, 25 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Rxsight files

Where Rxsight stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $128m, down 13.2% on a year earlier, a smaller fall than the 14.0% decline a quarter earlier. That puts it 57 of 58 for growth among the health care equipment companies we cover. Free-cash-flow margin fell to -21.3% from -14.2% a year earlier. Operating margin narrowed to -43.2% from -28.9%. The diluted share count is up 2.2% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 3 financial-health checks. Our revenue-to-maturity cash-flow model value is $4.22 a share, against a share price of $5.13.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Rxsight, Inc.'s trailing-twelve-month revenue fell 13.2% year on year, with a free-cash-flow margin of -21.3%. Where it stands out: gross margin of 77.5% ranks 22 of 123 health care equipment companies we cover. Where it lags: revenue growth of -13.2% ranks 117 of 129 health care equipment companies we cover.

Current signal Gross margin expanding: TTM gross margin reached 77.5%, up 4.4pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 13.2% over the last 12 months.
  • Loss-making. Operating margin is -43.2%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 14.3 points on a year ago.
  • Burning cash. Free cash flow was -21.3% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 24.6% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 2.2% in a year.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
-$0.11 against an average estimate of -$0.19: beat by 41.4%
Revenue
$34m, up 0.3% on a year earlier
Share reaction
-2.7% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 3, 2026; average EPS estimate -$0.19

Rxsight's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.4%
  • 1 week-2.6%
  • 1 month+2.6%
  • This year-53.9%
  • 1 year-45.4%
  • 5 years-62.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$128M
Operating margin
-43.2%
Net margin
-36.8%
EPS (TTM, diluted)
$-1.14

Growth

Revenue growth
−13.2%
Change in growth rate
+0.8 pts
Share count change
+2.2%

Cash

Free cash flow (TTM)
-$27.2M
FCF margin
-21.3%
Stock pay % of revenue
24.6%

Earnings

Last results
August 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Leadership
  3. Agreement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Rxsight, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Rxsight, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.06 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$4.3 ~$3.9–$4.5 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$4.4 ~$4.9–$17 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$4.2 ~$4.2–$4.5 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$4.3 ~$4.2–$4.4 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Rxsight, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$11.25$12.67$40.32$34.38$10.42$4.80
Market value$307m$350m$1.4bn$1.3bn$426m$198m
+ Net debt (− = net cash)$16m$28m−$10m−$17m−$20m−$13m
Enterprise value$322m$379m$1.4bn$1.3bn$406m$185m
Multiples
Price / sales 13.6x7.2x15.6x9.5x3.2x1.6x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

27 /100

Weak moat

How hard Rxsight's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -8.2% of total assets over 5 years.

  • Pricing power 12 / 20

    Gross margin has been a median 59.4%, moving by 22.3 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -64.6%; its worst year was -241.7%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -58.5% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close. Analysts expect revenue of $27m and EPS of −$0.19 (range −$0.31 to $0.09) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.28 −54% $147m +9%
Next −$0.68 −146% $149m +1%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −60.4% on 90 days ago. In the last 30 days, 4 analysts raised Rxsight, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Rxsight, Inc., last 90 days
−$0.80 −$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.70 Current fiscal year, 60 days ago: −$0.27 Current fiscal year, 30 days ago: −$0.27 Current fiscal year, 7 days ago: −$0.27 Current fiscal year, Now: −$0.28 −$0.28 Next fiscal year, 90 days ago: −$0.56 Next fiscal year, 60 days ago: −$0.70 Next fiscal year, 30 days ago: −$0.70 Next fiscal year, 7 days ago: −$0.70 Next fiscal year, Now: −$0.68 −$0.68

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.70−$0.56
60 days ago −$0.27−$0.70
30 days ago −$0.27−$0.70
7 days ago −$0.27−$0.70
Now −$0.28−$0.68

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.19 −$0.11 +41.4%
Mar 2026 −$0.15 −$0.19 −28.4%
Dec 2025 −$0.20 −$0.03 +84.8%
Sept 2025 −$0.26 −$0.04 +84.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

10 analysts, Oct 2026
Buy110%
Hold770%
Sell220%

Monthly trend

  1. Oct 202617210
  2. Sep 202617210
  3. Aug 202617210
  4. Jul 202617210

Counts of recommendations published by analysts covering Rxsight, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
10.4%
of tradable shares
Days to cover
5.26
at average volume
Short interest, 1 month
+4%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
6.6%
of shares
Employees
461
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −45.4%

$8.79 on October 31, 2025 to $4.80

ThenNowEffect
Revenue (last 12 months) $147m $128m −13.2%
P/S multiple 2.4x 1.6x −35.7%
Share count 40m 41m −2.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −80.1%

$24.17 on November 3, 2023 to $4.80

ThenNowEffect
Revenue (last 12 months) $67m $128m +90.4%
P/S multiple 11.0x 1.6x −85.9%
Share count 30m 41m −26.2%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
RXST+13%+218%−15%−70%−54%
Industry peers (median)−37%−9%−20%−16%−13%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
RXST50%67%58%25%27%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
RXST−40%−37%−48%−81%−57%
S&P 500−25%−10%−8%−19%−9%

Worst fall since July 30, 2021: 93% from May 15, 2024 to October 16, 2026. Getting back needed a 1326% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$4.51 – $13.09
From 52-week high
−63.3%
vs 50-day average
−10.5%
vs 200-day average
−24.3%
Volatility (1 year)
62%
Beta vs S&P 500
1.08

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
2 up, 10 down
typical move ±12.3%
After a week
4 up, 8 down
typical move ±16.1%
After a month
5 up, 7 down
typical move ±21.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −2.7% −0.4% +13.0% +4.6%
July 6, 2026 +0.2% +0.4% −9.8% +11.4%
May 6, 2026 −20.1% +1.1% −23.6% −31.1%
February 25, 2026 −11.4% +0.3% −11.3% −27.4%
January 12, 2026 +14.4% 0.0% +9.3% −9.2%
November 5, 2025 −4.3% −0.7% +11.2% +40.3%
August 7, 2025 −4.8% +0.7% +8.9% +18.4%
July 8, 2025 −36.0% +0.5% −40.1% −39.3%
May 7, 2025 −5.2% +1.1% −5.1% +7.8%
April 3, 2025 −37.7% −10.5% −45.7% −44.0%
February 25, 2025 −1.1% −0.4% −8.3% −16.8%
January 13, 2025 −10.0% +0.3% −7.4% −4.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Rxsight, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Rxsight, Inc.
$60M $80M $100M $120M $140M $160M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $76.6M Revenue (TTM), FY23 Q4: $89.1M Revenue (TTM), FY24 Q1: $101.1M Revenue (TTM), FY24 Q2: $115.2M Revenue (TTM), FY24 Q3: $128.3M Revenue (TTM), FY24 Q4: $139.9M Revenue (TTM), FY25 Q1: $148.3M Revenue (TTM), FY25 Q2: $147.1M Revenue (TTM), FY25 Q3: $142.1M Revenue (TTM), FY25 Q4: $134.5M Revenue (TTM), FY26 Q1: $127.5M Revenue (TTM), FY26 Q2: $127.6M $127.6M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $76.6M
FY23 Q4 $89.1M
FY24 Q1 $101.1M
FY24 Q2 $115.2M
FY24 Q3 $128.3M
FY24 Q4 $139.9M
FY25 Q1 $148.3M
FY25 Q2 $147.1M
FY25 Q3 $142.1M
FY25 Q4 $134.5M
FY26 Q1 $127.5M
FY26 Q2 $127.6M
Revenue growth, TTM YoY Rxsight, Inc.
-50% 0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 85.2% Revenue growth, TTM YoY, FY23 Q4: 81.8% Revenue growth, TTM YoY, FY24 Q1: 75.7% Revenue growth, TTM YoY, FY24 Q2: 71.9% Revenue growth, TTM YoY, FY24 Q3: 67.5% Revenue growth, TTM YoY, FY24 Q4: 57.1% Revenue growth, TTM YoY, FY25 Q1: 46.7% Revenue growth, TTM YoY, FY25 Q2: 27.7% Revenue growth, TTM YoY, FY25 Q3: 10.8% Revenue growth, TTM YoY, FY25 Q4: -3.9% Revenue growth, TTM YoY, FY26 Q1: -14.0% Revenue growth, TTM YoY, FY26 Q2: -13.2% -13.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 85.2%
FY23 Q4 81.8%
FY24 Q1 75.7%
FY24 Q2 71.9%
FY24 Q3 67.5%
FY24 Q4 57.1%
FY25 Q1 46.7%
FY25 Q2 27.7%
FY25 Q3 10.8%
FY25 Q4 -3.9%
FY26 Q1 -14.0%
FY26 Q2 -13.2%
Operating margin (TTM) Rxsight, Inc.
-80% -60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -70.8% Operating margin (TTM), FY23 Q4: -56.2% Operating margin (TTM), FY24 Q1: -47.1% Operating margin (TTM), FY24 Q2: -36.8% Operating margin (TTM), FY24 Q3: -30.5% Operating margin (TTM), FY24 Q4: -26.3% Operating margin (TTM), FY25 Q1: -24.9% Operating margin (TTM), FY25 Q2: -28.9% Operating margin (TTM), FY25 Q3: -32.0% Operating margin (TTM), FY25 Q4: -35.8% Operating margin (TTM), FY26 Q1: -43.4% Operating margin (TTM), FY26 Q2: -43.2% -43.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -70.8%
FY23 Q4 -56.2%
FY24 Q1 -47.1%
FY24 Q2 -36.8%
FY24 Q3 -30.5%
FY24 Q4 -26.3%
FY25 Q1 -24.9%
FY25 Q2 -28.9%
FY25 Q3 -32.0%
FY25 Q4 -35.8%
FY26 Q1 -43.4%
FY26 Q2 -43.2%
FCF margin (TTM) Rxsight, Inc.
-80% -60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -66.2% FCF margin (TTM), FY23 Q4: -52.1% FCF margin (TTM), FY24 Q1: -38.7% FCF margin (TTM), FY24 Q2: -30.7% FCF margin (TTM), FY24 Q3: -21.2% FCF margin (TTM), FY24 Q4: -16.0% FCF margin (TTM), FY25 Q1: -13.8% FCF margin (TTM), FY25 Q2: -14.2% FCF margin (TTM), FY25 Q3: -15.6% FCF margin (TTM), FY25 Q4: -14.4% FCF margin (TTM), FY26 Q1: -16.9% FCF margin (TTM), FY26 Q2: -21.3% -21.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -66.2%
FY23 Q4 -52.1%
FY24 Q1 -38.7%
FY24 Q2 -30.7%
FY24 Q3 -21.2%
FY24 Q4 -16.0%
FY25 Q1 -13.8%
FY25 Q2 -14.2%
FY25 Q3 -15.6%
FY25 Q4 -14.4%
FY26 Q1 -16.9%
FY26 Q2 -21.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 15 23 49 89 140 134 128
Gross profit 2 5 21 54 99 103 99
EBITDA −32 −49 −59 −46 −33 −45 −52
Operating income −35 −53 −63 −50 −37 −48 −55
Net income 28 −49 −67 −49 −27 −39 −47
Diluted EPS $0.07 −$1.78 −$2.41 −$1.41 −$0.71 −$0.95 −$1.14
Growth (year on year)
Revenue — +53.9% +116.9% +81.8% +57.1% −3.9% −13.2%
Net income — −276.6% — — — — —
Diluted EPS — <−999% — — — — —
Margins
Gross margin 11.6% 20.0% 43.5% 60.4% 70.7% 76.6% 77.5%
EBITDA margin −215.0% −216.0% −121.3% −51.6% −23.8% −33.4% −40.4%
Operating margin −241.3% −233.6% −129.2% −56.2% −26.3% −35.8% −43.2%
Net margin 187.9% −215.5% −136.2% −54.6% −19.6% −29.0% −36.8%
Free-cash-flow margin −257.1% −206.5% −125.0% −52.1% −16.0% −14.4% −21.3%
Cash flow
Cash from operations −35 −45 −59 −42 −17 −16 −23
Capital spending 3 2 2 5 5 4 4
Free cash flow −38 −47 −61 −46 −22 −19 −27
Stock-based pay 4 8 11 16 25 32 31
Free cash flow after stock pay −42 −54 −73 −62 −47 −51 −59
Balance sheet
Cash 14 24 12 10 17 20 13
Total debt 24 40 40 0 0 0 0
Net debt (negative = net cash) 10 16 28 −10 −17 −20 −13
Diluted shares 11m 27m 28m 34m 39m 41m 41m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $353m
Short-term assets $327mLonger-term assets $25m
What it owes, and who funded it · $353m
Short-term liabilities $80mLonger-term liabilities $9mShareholders' equity $263m
  • Short-term assets cover short-term liabilities $327m of assets due within a year against $80m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $327m short-term assets against $9m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$55m against $15,000 of interest.

From Rxsight, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+2.2%
year over year
R&D spending
28.7%
of revenue
Sales & admin spending
92.0%
of revenue
Days sales outstanding
53 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated RXST BBNX ANIK OM OWLT INFU Median
Revenue, last 12 months $128m $127m $121m $118m $115m $143m $99m
Revenue growth, last 12 months −13.2% 43.7% 5.3% −1.3% 28.2% 2.5% 9.2%
Revenue growth, 3-year average 23.9% — 0.3% −3.1% 29.3% 6.6% 13.5%
Revenue growth, latest quarter 0.3% 30.3% 15.6% 0.7% 29.9% 2.6% 10.2%
Gross margin 77.5% 58.6% 62.2% 41.8% 54.8% 57.5% 61.2%
Operating margin −43.2% −72.7% −4.2% −56.1% −6.3% 9.3% −8.5%
Operating margin, 3-year average −36.3% — 0.2% −83.8% −17.9% 6.6% −17.9%
Net margin −36.8% −65.3% −3.1% −63.1% −7.7% 6.0% −12.0%
Cash from operations / revenue −17.8% −46.6% 5.0% −32.5% −6.8% 16.3% −1.9%
Free-cash-flow margin −21.3% −51.8% 0.5% −33.0% −7.4% 16.0% −3.9%
Free-cash-flow margin, 3-year average −22.1% — 0.4% −70.2% −14.1% 14.2% −7.0%
Stock pay / revenue 24.6% 18.4% 10.9% 13.0% 11.2% 3.5% 6.1%
Change in share count 2.2% 44.6% −4.0% 311.4% 72.6% −2.4% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth -13.2% 9.1% 117 of 129
Change in growth rate Growth +0.8pp -0.6pp 44 of 129
Gross margin Profitability 77.5% 61.9% 22 of 123
Operating margin Profitability -43.2% -8.3% 86 of 132
Net margin Profitability -36.8% -12.0% 82 of 133
Free-cash-flow margin Cash generation -21.3% -3.4% 81 of 128
Stock pay as % of revenue Cash generation 24.6% 6.1% 103 of 123
Change in share count Balance sheet 2.2% 3.3% 48 of 115
Days sales outstanding Balance sheet 53 days 57 days 50 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Rxlal $108M 80.4% ▲ 12.0%
LDD $20.7M 15.4% ▼ 47.9%
Service Warranty Service Contracts and Accessories $5.7M 4.3% ▲ 54.3%

From Rxsight, Inc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$200M
Institutions reporting
150
Shares held vs prior quarter
▲ 8.6%
Positions opened / closed
24 / 34

Top buyers and sellers, Q2 2026: 94 institutions bought and 69 sold ; the biggest buyer was Blackrock, Inc (+2.6M shares) and the biggest seller Artisan Partners Limited Partnership (−2.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $27.9M 5.8M 14.0% ▲ 81.7%
Millennium Management LLC $14.6M 3.0M 7.3% ▲ 47.1%
No Street Gp LP $9.9M 2.1M 5.0% ▲ 2.8%
Nomura Holdings Inc $9.6M 2.0M 4.8% 0.0%
D. E. Shaw & Co., Inc. $9.6M 2.0M 4.8% ▲ 1.3%
Vanguard Capital Management LLC $8.1M 1.7M 4.0% ▼ 1.0%
AQR Capital Management LLC $7.4M 1.5M 3.7% ▲ 141.1%
Acadian Asset Management LLC $7.2M 1.5M 3.6% ▲ 47.3%
Federated Hermes, Inc. $5.8M 1.2M 2.9% ▲ 11.1%
Two Sigma Investments, LP $5.5M 1.1M 2.8% ▼ 11.8%
Healthcare Of Ontario Pension Plan Trust Fund $5.5M 1.1M 2.7% 0.0%
UBS Group AG $4.9M 1.0M 2.5% ▲ 324.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Rxsight, Inc.'s complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $117,951 4 trades by 4 insiders · 0% under pre-set plans
Net ▼ $117,951 net selling
Insider Date Trade Shares Price Value
Weinberg Eric See remarks September 2, 2026 Sell 2,041 $6.96 $14,205
Goldshleger Ilya Chief Operating Officer September 2, 2026 Sell 2,041 $6.96 $14,205
Wilterding Mark Chief Financial Officer September 2, 2026 Sell 7,765 $6.96 $54,044
Kurtz Ronald M Md Chief Medical Officer September 2, 2026 Sell 5,100 $6.96 $35,496

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 5, 2026
  • July 6, 2026
  • May 6, 2026
  • February 25, 2026
  • January 12, 2026
  • November 5, 2025

Recent SEC filings

Data status

When each part of this page on Rxsight, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Rxsight, Inc. in brief

What does Rxsight, Inc. do?
Rxsight, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Rxsight, Inc.'s stock ticker?
Rxsight, Inc. trades under the ticker RXST on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Rxsight, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Rxsight, Inc. reported revenue of $128M, 13.2% lower than a year earlier, according to its SEC filings.
What is Rxsight, Inc.'s free cash flow?
Rxsight, Inc.'s free-cash-flow margin is -21.3% of revenue over the trailing twelve months, ranking 81 of the 128 health care equipment companies we cover.
Who are Rxsight, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Millennium Management LLC and No Street Gp LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Rxsight, Inc.'s market cap?
On November 2, 2026, Rxsight, Inc.'s market capitalisation was about $198M and net debt of -$13.4M. Market figures come from third-party market data and may be delayed.
Who are Rxsight, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Rxsight, Inc. are Beta Bionics, Inc., Anika Therapeutics, Inc., Outset Medical, Inc., Owlet, Inc. and Infusystem Holdings, Inc. The side-by-side comparison below sets their revenue, margins and growth against Rxsight, Inc.'s.
Are insiders buying or selling Rxsight, Inc. stock?
Over the last 12 months, Rxsight, Inc.'s directors and officers reported 0 open-market purchases and 4 sales on Form 4. The insider trading page charts every trade.
When is Rxsight, Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Rxsight, Inc. announces its own schedule.